Macrilen


Jason Kolbert Believes AEterna Zentaris Inc. (USA) (AEZS) Is “Deeply Undervalued;” Shares Leap 64% Following FDA Win for AGHD Drug

Maxim’s Jason Kolbert bets AEZS’ oral test could set a new standard in addressing Adult Growth Hormone Deficiency (AGHD) with FDA approval now under its belt.

AEterna Zentaris Inc.’s (USA) (AEZS) Growth Hormone Drug Accepted for EU Review

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that the Marketing Authorization Application (MAA) for the use of Macrilen™ (macimorelin) for the evaluation of adult …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts